Page 7 - Cancer Drugs

AstraZeneca's cancer drug shows more potential over chemotherapy: Study

The results potentially validate Astra's decision to pay as much as $6 billion for the right to develop the medicine with Daiichi Sankyo Co. and its bet to revive growth a decade ago

Lupin gets $25 mn from AbbVie for meeting key product development milestone

Drug firm Lupin on Thursday said it has received USD 25 million (around Rs 205 crore) from AbbVie Inc for meeting a key development milestone for a product to treat hematological cancers. The company has achieved a key milestone for its novel MALT1 (Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1) inhibitor program that is partnered with AbbVie Inc towards treatment across a range of hematological cancers, the Mumbai-based drug maker said in a statement. As part of the agreement, Lupin has received USD 25 million from AbbVie for initiation of Phase 1 clinical studies successfully, it added. The drug maker had earlier received USD 30 million from AbbVie for achievement of other milestones in the programme. "This achievement is further validation of our ability to successfully develop novel treatments for unmet needs. We look forward to continued successful development of this important treatment for patients with difficult-to-treat cancers," Lupin Managing Directo

US FDA to temporarily import Chinese cancer drug to ease shortage

Cisplatin, a generic drug available for decades in the US, has faced national shortage since February after an Indian pharmaceutical company temporarily halted production for the US market

New combination therapy cuts risk of breast cancer returning by 25%

The median duration of study follow-up was 34 months, with three-year and two-year duration of ribociclib completed by 20 per cent and 57 per cent patients respectively

Sun Pharma, Philogen join hands to commercialise skin cancer drug in Europe

Sun Pharmaceutical Industries on Tuesday said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand. The companies have come together to commercialise Philogen's speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement. Philogen, a Swiss-Italian firm, is developing it for the treatment of melanoma and non-melanoma skin cancers. Under the terms of the agreement, the Mumbai-based drug major will have exclusive rights to commercialise Nidlegy. Philogen will complete pivotal clinical trials for the product in Europe, pursue marketing authorisation with the regulatory authorities and manufacture commercial supplies. The two partner companies will share post-commercialisation economics in about a 50:50 ratio, the drug major said. While other financial terms were not disclosed, Philogen will retain the IP rights for Nidlegy

US FDA panel backs restricted use of AstraZeneca's prostate cancer drug

Lynparza is already approved by the FDA to treat a type of breast cancer, ovarian cancer, as well as a different form of prostate cancer

J&J May Need to Defend Baby Powder Cancer Suits After 19-Month Pause

The company says it has a deal backed by as many as 80,000 claimants, which should be enough to meet a key legal threshold to push a settlement worth $8.9 billion through bankruptcy

BioNTech signs deal to co-develop OncoC4's cancer antibody drug

A late-stage trial for the drug has been planned for this year, the companies said

Seagen acquisition: Pfizer can now bet on future of cancer drugs

Given the muted response to the deal on Monday, analysts seem skeptical that this will be as easy as Pfizer makes it sound

AstraZeneca gets CDSCO nod for drug to treat biliary tract cancer

Drug firm AstraZeneca India on Friday said it has received approval from the domestic drug regulator to market a drug to treat biliary tract cancer (BTC) in the country. The company has received approval from the Central Drugs Standard Control Organisation (CDSCO) for Durvalumab, the drug firm said in a statement. BTC is a group of rare and aggressive gastrointestinal (GI) cancers that form in the cells of the bile ducts (cholangiocarcinoma), gallbladder or ampulla of Vater (where the bile duct and pancreatic duct connect to the small intestine). Apart from ampullary cancer, early-stage BTC often presents without clear symptoms and most new cases of BTC are therefore diagnosed at an advanced stage, when treatment options are limited, and the prognosis is poor. More than 30,000 new cases of BTC are seen in India every year with 90 per cent of them diagnosed in the advanced stage. "The approval underpins our commitment to transform patient outcomes by harnessing the power of science

Glenmark Pharma inks settlement pact with Pfizer for cancer treatment drug

Glenmark Pharmaceuticals on Tuesday said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug. The Mumbai-based drug maker and its US-based unit have inked a settlement pact with drug major Pfizer Inc for Axitinib Tablets (1 mg and 5 mg). Glenmark's product is the generic version of Pfizer's Inlyta tablets, used to treat kidney cancer. According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million. Glenmark said its current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 abbreviated new drug applications (ANDA's) are pending for approval with the US Food and Drug Administration. Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE.

Novartis signs world's first licensing deal for high-priced cancer drug

The oral drug, nilotinib, is used to treat chronic myeloid leukemia and may be made in Egypt, Guatemala, Indonesia, Morocco, Pakistan, the Philippines, and Tunisia

Q3 results: Johnson & Johnson beats estimates on demand for cancer drug

The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could weigh on 2023 profit

Zydus gets USFDA nod to sell its cancer medicine in American market

Zydus Lifesciences on Tuesday said it has received approval from the US health regulator to sell Lenalidomide capsules, used in the treatment of various types of cancers, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market the product in strengths of 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg. Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders. The drug maker said the drug will be manufactured at the group's formulation facility at Ahmedabad SEZ. "We remain focused on providing patients access to affordable medication and USFDA approval of Lenalidomide Capsules, an important oncology therapy product, is yet another step in this endeavour," Zydus Lifesciences Managing Director Sharvil Patel stated. According to IQVIA MAT July data, Lenalidomide had annual sales of USD

Antibiotics might worsen melanoma cancer by depleting gut microbiome: Study

According to a new study by researchers at Emory University in Atlanta, the use of broad-spectrum antibiotics in mice with malignant melanoma, an aggressive form of skin cancer

Breast cancer among men slowly on the rise & usually detected late: Doctors

The disease is now being diagnosed in relatively younger men

Streamlining trade margins on drugs priced Rs 100 and above likely

Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first

Gene therapy to cure leukemia at one-tenth global costs in the works

ImmunoACT, backed by Laurus Labs is testing their cancer product

Indian origin patient among those healed completely of cancer in drug trial

An Indian origin patient was among those who had a "miracle" cure using a cancer medication that is being tried out by a research centre here achieving an unprecedented healing rate

Aurobindo Pharma gets USFDA nod to market generic cancer drug Bortezomib

Drug major Aurobindo Pharma on Wednesday said its wholly-owned subsidiary has received approval from the US health regulator to market anti-cancer medication Bortezomib for injection. Eugia Pharma Specialties has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market the product, a generic equivalent of Takeda Pharmaceuticals' Velcade for injection, the Hyderabad-based company said in a statement. The product, which is indicated for the treatment of multiple myeloma (cancer of plasma cells) and mantle cell lymphoma (cancer of lymph nodes), is being launched immediately, it added. According to IQVIA, the approved product has a market size of USD 1,172 million for the twelve months ending March 2022.